Life Sciences

5 Things to Know About Moderna's Proposed $500 Million IPO

5 Things to Know About Moderna's Proposed $500 Million IPO

Equities Research | |

The proposed deal for this biotechnology unicorn would be the largest US IPO in the industry (Image: Moderna)

Alpine Immune Sciences Shows Positive Preclinical Data for Cancer Immunotherapy

Equities Research | |

ALPN-202 combines dual checkpoint blockade action with T-cell costimulation

Mirum Pharmaceuticals Launches with $120 Million Series A and Phase 3-Ready Candidate for Rare Liver Diseases

Equities Research | |

Financing led by NEA. Drug candidate licensed from Shire for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

AVEO Oncology Shows Positive Phase 3 Results in Renal Cell Carcinoma

Equities Research | |

Tivozanib showed 44% improvement in progression free survival and 26% reduction in risk of progression or death compared to sorafenib (Image: AVEO Pharmaceuticals)

Infinity Pharmaceuticals Expands Clinical Collaboration with Bristol-Myers Squibb to Urothelial Cancer

Equities Research | |

Expansion of 2016 deal to evaluate Infinity PI3K-gamma inhibitor in combination with BMY's Opdivo (Image: Infinity Pharmaceuticals)

How Artificial Intelligence is Transforming Clinical Trial Recruitment

Visual Capitalist | |

Poor clinical trial recruitment can cause losses up to $8 million each day. How can health and pharma companies get better at finding the right patients?

Aquestive Gets FDA Approval for Oral Film Formulation of Clobazam for LGS Seizures

Equities Research | |

First oral film formulation of clobazam, for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (Image: Aquestive Therapeutics)

Denali Therapeutics Signs Neurodegenerative and Inflammatory Disease Collaboration with Sanofi

Equities Research | |

$125 million upfront + potentially over $1 billion in milestone payments to develop RIPK1 inhibitors (Image: Denali Therapeutics)

Tango Therapeutics Signs Immuno-Oncology Collaboration with Gilead

Equities Research | |

$50 million upfront + up to $1.7 billion in milestone payments (Image: Tango Therapeutics)

Orchard Therapeutics' $200 Million IPO Expected This Week for Gene Therapy Programs

Equities Research | |

Autologous gene therapy for rare diseases including primary immune deficiencies, inherited metabolic disorders and blood disorders (Image: Orchard Therapeutics).

Emerging Growth


Nxt-ID Inc provides products, solutions, and services that have a need for biometric secure access control. Its lines of business include mobile commerce; law enforcement and biometric access control applications…


BIO CEO & Investor Conference

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to…

Learn more